SYNTHETIC BIOLOGICS
Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery-stage biotherapeutics for the treatment of phenylketonuria.
SYNTHETIC BIOLOGICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2001-01-01
Address:
Rockville, Maryland, United States
Country:
United States
Website Url:
http://www.syntheticbiologics.com
Total Employee:
11+
Status:
Active
Contact:
(734) 332-7800
Email Addresses:
[email protected]
Total Funding:
32.88 M USD
Technology used in webpage:
Euro Font Awesome Common Name Invalid CPanel
Similar Organizations
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Inovio Pharmaceuticals
Inovio is a biotech company focusing on bringing to market DNA medicines for diseases associated with HPV, cancer, and infectious diseases.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Society for Muscle Biology
Society for Muscle Biology is understanding and expanding the knowledge about muscle include development, function, genetics, and disease.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-12-14 | VCN Biosciences | VCN Biosciences acquired by Synthetic Biologics | N/A |
Investors List
MSD Partners
MSD Partners investment in Post-IPO Equity - Synthetic Biologics
Biotechnology and Biological Sciences Research Council
Biotechnology and Biological Sciences Research Council investment in Grant - Synthetic Biologics
Engineering and Physical Sciences Research Council
Engineering and Physical Sciences Research Council investment in Grant - Synthetic Biologics
Randal J. Kirk
Randal J. Kirk investment in Post-IPO Equity - Synthetic Biologics
Official Site Inspections
http://www.syntheticbiologics.com
- Host name: cpanel141.turbify.biz
- IP address: 34.235.229.86
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Synthetic Biologics"
Synthetic Biologics, Inc.
Synthetic Biologics, Inc. www.syntheticbiologics.com Updated 11.23.2021 December 2021See details»
Synthetic Biologics Rebrands as Theriva Biologics
Oct 12, 2022 Cookie Duration Description __cf_bm: 1 hour: This cookie, set by Cloudflare, is used to support Cloudflare Bot Management. _cfuvid: session: The _cfuvid cookie is used to allow the Cloudflare WAF to distinguish individual โฆSee details»
Synthetic Biologics Announces Management Transitions in โฆ
Mar 23, 2022 -Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating Officer of VCN Biosciences- -Manel Cascallฯ, Ph.D., โฆSee details»
Synthetic Biologics Announces Management Transitions in โฆ
Mar 23, 2022 Cookie Duration Description __cf_bm: 1 hour: This cookie, set by Cloudflare, is used to support Cloudflare Bot Management. _cfuvid: session: The _cfuvid cookie is used to โฆSee details»
Synthetic Biologics Company Profile | Management and
Www.syntheticbiologics.com Synthetic Biologics Profile and History Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the gut โฆSee details»
Synthetic Biologics, Inc. Information - RocketReach
What is the annual revenue of Synthetic Biologics, Inc.? The Synthetic Biologics, Inc. annual revenue was $5.4 million in 2024.See details»
Synthetic Biologics Completes Acquisition of VCN Biosciences
Mar 11, 2022 โ Expands pipeline into oncology with unique, clinical-stage oncolytic viruses optimized for intravenous administration โ โ Strong cash position to support multiple inflection โฆSee details»
Synthetic Biologics, Inc. Company Information - Drugs.com
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for โฆSee details»
Synthetic Biologics - Overview, News & Similar companies
Sep 30, 2022 Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022 ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE โฆSee details»
Synthetic Biologics Reports 2020 Year End Operational Highlights โฆ
Mar 4, 2021 For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com. This release contains forward-looking statements within the โฆSee details»
Synthetic Biologics Announces Formation of Scientific Advisory โฆ
May 5, 2022 Scientific Advisory Board of leading experts in oncolytic adenoviruses and gene therapies strengthens transformative clinical development strategy and extension into โฆSee details»
Synthetic Biologics, Inc - Cruelty Free Investing
Synthetic Biologics, Inc. is a clinical stage company, which develops therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. Its products portfolio includes SYN โฆSee details»
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2021 ...
The press release can be found in the Investors section of the company website at www.syntheticbiologics.com, together with the annual report on Form 10-K for the year ended โฆSee details»
Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a ...
Apr 14, 2021 For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com. This release contains forward-looking statements within the โฆSee details»
Synthetic Biologics Reports 2021 Year End Operational Highlights โฆ
Mar 16, 2022 For the year ended December 31, 2021 : 2020 : Operating Costs and Expenses: General and administrative $ 6,474 $ 5,029 : Research and developmentSee details»
Synthetic Biologics to Host Conference Call and Webcast to
ROCKVILLE, Md., March 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to โฆSee details»
Synthetic Biologics Provides Update on Investigator-Sponsored โฆ
Oct 2, 2020 For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com. This release contains forward-looking statements within the โฆSee details»
Synthetic Biology
Aardvark Therapeutics, a San Diego-based biotech company, is on track for an initial public offering (IPO) this summer. The company is developing a we...See details»
SynBio Canada
Nov 15, 2024 SynBio Canada aims to establish Canada as a leader in the field of synthetic biology, by bringing together academics, industry partners, and the general public to learn and โฆSee details»
DELIVERING A NEW CLASS OF ONCOLYTIC VIRUS THERAPEUTICS
Oct 31, 2024 Cookie Duration Description __cf_bm: 1 hour: This cookie, set by Cloudflare, is used to support Cloudflare Bot Management. _cfuvid: session: The _cfuvid cookie is used to โฆSee details»